MISSION STATEMENT

As a nonprofit organization, ASCO is dedicated to achieving its charitable mission outlined by the organization’s founders in 1964. ASCO strongly supports all types of cancer research, but in particular, patient-oriented clinical research.

ASCO is committed to
Improving cancer care and prevention;
Advancing the education of physicians and other professionals in the care of patients with cancer and supporting research and the development of clinical cancer researchers;
Fostering communication among cancer-related medical subspecialties and the exchange of a wide range of ideas related to cancer, including its biology, prevention, diagnosis, staging, treatment, and psychosocial impact;
Advocating public policy that ensures patient access to high-quality cancer care and that supports increased clinical cancer research; and
Assisting oncologists in addressing the challenges of the modern-day practice of oncology.

Core Values
Commitment: ASCO’s overriding concerns are the care and well-being of patients with cancer.
Integrity: ASCO will strive for integrity and trustworthiness in all endeavors.
Competence: ASCO will work to ensure excellence in care for all patients with cancer.
Innovation: ASCO is committed to innovation in research, oversight, and delivery of cancer care.
Inclusivity: ASCO is committed to professional diversity and multidisciplinary care for patients with cancer.
Dear ASCO Members and Colleagues:

We are pleased to present to our members this report on the Society’s activities of the last twelve months. ASCO continues to be the premier oncology professional society. We have successfully met the needs of our members—domestic, international, community, academic, and those in the various oncologic subspecialties—for cancer-related education and for venues to disseminate their research findings. In these pages, you will read of new and expanding offerings in the traditional print and live meeting format, as well our Society’s expanding electronic platforms, for dissemination of the latest findings in clinical, translational, prevention and outcomes research. In addition, we continue to develop a broad variety of professional educational products and services, and continue to develop new member services. We’re sure that you’ll be pleased.

The 2009 theme of “Personalizing Cancer Care,” chosen by Dr. Richard L. Schilsky, captured the thrust of the translational discoveries made daily by our members and introduced to the broader community in our journals and meetings. In this report you will read of new and expanding offerings in the traditional print and live meeting format, as well our Society’s expanding electronic platforms, for dissemination of the latest findings in clinical, translational, prevention and outcomes research. In addition, we continue to develop a broad variety of professional educational products and services, and continue to develop new member services. We’re sure that you’ll be pleased.

The 2009 theme of “Personalizing Cancer Care,” chosen by Dr. Richard L. Schilsky, captured the thrust of the translational discoveries made daily by our members and introduced to the broader community in our journals and meetings. In this report you will read of new and expanding offerings in the traditional print and live meeting format, as well our Society’s expanding electronic platforms, for dissemination of the latest findings in clinical, translational, prevention and outcomes research. In addition, we continue to develop a broad variety of professional educational products and services, and continue to develop new member services. We’re sure that you’ll be pleased.

“Advancing Quality through Innovation” is the presidential theme for the 2010 Annual Meeting and the activities leading up to it, chosen by Dr. Douglas W. Blayney. In 2010 we will continue to highlight the latest clinical innovations, but also highlight our members’ activities in defining, delivering, measuring the quality of care provided to each and every one of our patients and cancer survivors, and improving that care when needed.

Given the changing policy and regulatory environment in which all voluntary professional societies operate, ASCO’s governance activities were also given some attention this year. The Board of Directors devoted time at each of our quarterly meetings to managing the Society’s strategies—reviewing existing strategy efforts and developing new efforts to assure the viability of our profession and its service to our patients. This report also shows that the Society successfully weathered the difficult 2009 economic situation which challenged all professional societies.

We continue to enhance the quality of our membership experience through innovation. Please enjoy this report on our progress.

Best Regards,

Richard L. Schilsky, MD
ASCO President 2008-2009

Douglas W. Blayney, MD
ASCO President 2009-2010

LETTER FROM ASCO’S PAST AND CURRENT PRESIDENTS

Dear ASCO Members and Colleagues:

I am pleased to present the 2009 ASCO Annual Report, a summary of new initiatives that have been developed in support of the Society’s mission and information about new programs and services.

A focus of ASCO leadership in 2009 has included issues surrounding access to high-quality cancer care, cancer research advocacy, workforce development, and education, and these topics provide the central themes around which information in the Annual Report is organized.

ASCO is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. Our efforts are also directed toward advocating policies that provide access to high-quality care for all patients with cancer and supporting the increased funding for clinical and translational research.

Our meetings, journals, and policy initiatives are designed to inform and assist ASCO members in providing better care to our patients. I would like to express my deepest gratitude to the committee members and volunteers who are integral to the success of these programs. ASCO continues to strive to be a leading force in oncology care, education, research and service around the world.

I hope you enjoy reading the 2009 ASCO Annual Report.

Sincerely,

Allen S. Lichter, MD
CEO
I. Quality Care

In 2009 the Society addressed cost of care and quality issues with the development of a guidance statement, initiatives, and safety standards to help oncologists and the health care team continue to provide high-quality care.

ASCO, ONCOLOGY NURSING SOCIETY PUBLISH STANDARDS FOR SAFE CHEMOTHERAPY ADMINISTRATION

In a move referred to as “a watershed moment in oncology” by ASCO’s CEO Allen S. Lichter, MD, ASCO and the Oncology Nursing Society (ONS) developed a set of Standards for Safe Chemotherapy Administration. These 31 first-ever national standards are intended for adults in an outpatient setting, the circumstances under which most chemotherapy is administered in the United States. The Standards for Safe Chemotherapy Administration were published in full in the September 28, 2009 issue of the Journal of Clinical Oncology (JCO).

The ASCO/ONS chemotherapy safety standards are intended to reduce the risk of errors when providing patients with chemotherapy and to provide a framework for best practices in cancer care. Specifically, they can inform practice policies and procedures, internal quality assessment, and external quality monitoring.

The ASCO/ONS chemotherapy safety standards development process was initiated with a review of the literature and convening of a workshop of 40 multidisciplinary oncology professionals, representing diverse practice settings, including oncologists, nurses, pharmacists, social workers, practice administrators and patient advocates. Workshop participants drafted a set of standards that were published online in a public survey to gain comments and insight from all stakeholders. The feedback from the public survey was incorporated into the standards generated by the workshop participants, resulting in the finalized set of Standards for Safe Chemotherapy Administration.

ASCO published online resources to help practices ensure compliance with the ASCO/ONS standards. Also, the ASCO/ONS safety standards have been integrated into the Site Assessment component of the QOPI® Certification Program.

Mary Wilkinson, MD, is an oncology practitioner at Medical Oncology and Hematology Associates of Northern Virginia.

The goal of all cancer care providers should be adherence to safe chemotherapy administration standards.

Joseph Jacobson, MD, lead author of the chemotherapy administration safety standards
COST OF CARE RESOURCES FOR PHYSICIANS, PATIENTS

The cost of cancer treatment is often identified by patients with cancer as one of the most pressing issues they face. ASCO is concerned that the rising costs of health care in general, and cancer care specifically, are not sustainable.

To address this issue, ASCO created resources and educational opportunities for members to raise awareness about the rising costs of cancer care and how to discuss cost issues with patients.

- The ASCO Cost of Cancer Care Task Force developed the ASCO Guidance Statement: The Cost of Cancer Care.
- The Cancer Education Committee included sessions on the cost of care in the 2009 ASCO Annual Meeting educational program.
- ASCO developed a booklet called “Managing the Cost of Cancer Care” to help patients start and guide a conversation with their health care team about coping with costs of cancer care.

Cost of Cancer Care Guidance Statement

The Cost of Cancer Care Guidance Statement was developed to raise awareness about the rising cost of cancer care and to educate clinical oncologists and other stakeholders about the role each plays in addressing the issue of cost in the context of quality care.

The statement was developed by the ASCO Cost of Care Task Force, with Lowell Schnipper, MD, of Beth Israel Deaconess Medical Center serving as Chair. The Task Force believes that change needs to begin in the oncology community and has recommended initial steps for the community to take to begin addressing the high cost of cancer care:

- Discussion of Cost as an Important Component of High-quality Care. ASCO affirms the critical role of oncologists in addressing cost of care with their patients. ASCO believes that communication with patients about the cost of care is a key component of high-quality care.
- Physician Education. ASCO is committed to the development and dissemination of clinical support tools to help prepare oncologists to engage in cost discussions with their patients.
- Patient Education. ASCO will work with others in the oncology community to assure availability of resources that integrate cost of treatment and other information to support patient decision making.
- Addressing the Underlying Factors Contributing to the Increasing Cost of Cancer Care. ASCO recognizes that the factors underlying increasing costs of cancer care are multifactorial and occur in the context of a health care system that is not integrated, is poorly coordinated, and values clinical interventions, the uses of advanced technology, and cognitive care in markedly different ways.
Increasingly, oncology practices are being asked by payors, patients, and others to attest to the quality of care they provide...QOPI Certification will demonstrate a practice’s commitment to delivering high-quality cancer care.

2009-2010 ASCO President Douglas W. Blayney, MD
CLINICAL PRACTICE GUIDELINES CONSIDERED ONE OF THE TOP BENEFITS OF MEMBERSHIP

Guidelines can help reduce variations in practice, increase the quality of care, offer decision support, and help providers ensure they are delivering evidence-based care. ASCO guidelines provide a comprehensive review of the literature, interpret clinical trial results, and provide expert guidance about new therapies and technologies in oncology. Recommendations are based on intensive review ASCO provides for each guideline.

CLINICAL PRACTICE GUIDELINES ISSUED

- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
  www.asco.org/guidelines/bcrr
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
  www.asco.org/guidelines/5ari
  www.asco.org/guidelines/protectants
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer
  *JCO* Early Release, published online ahead of print Nov. 16, 2009.
  www.asco.org/guidelines/nsclc
ASCO RELEASES FIRST PROVISIONAL CLINICAL OPINION

ASCO released a Provisional Clinical Opinion (PCO) in January 2009. PCOs are intended to offer timely preliminary clinical direction to oncologists following the publication or presentation of potentially practice-changing data from major studies.

“Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy,” addresses the importance of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy with cetuximab or panitumumab. www.asco.org/pco/kras

ASCO PUBLISHES CLINICAL EVIDENCE REVIEW

In 2009 ASCO published, “American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer.” Clinical evidence reviews are a systematic review of existing literature on topics of interest to the oncology community. These reviews address areas associated with clinical uncertainty and likely practice variation, but for which there are insufficient data to inform practice recommendations. www.asco.org/guidelines/cer/rfa

BREAST CANCER REGISTRY PILOT PROGRAM DEBUTS

The Society launched the ASCO Breast Cancer Registry Pilot Program, funded by Susan G. Komen for the Cure®. The program seeks to improve communication and care coordination for patients and to collect data in a registry that can be used for practice-based quality improvement activities and national quality monitoring for breast cancer care.

Twenty diverse oncology practices are pilot testing the Registry. The Registry Pilot Program will continue until December 2010 and is overseen by the ASCO Registry Steering Group. Using a web-based application, participating oncologists and their staff enter clinical data about every newly diagnosed patient with stage 0 through stage III breast cancer into the Registry. They then generate and discuss the treatment plans and summaries with all of their patients during the pilot period.

“The Registry Pilot Program] will not only support oncology providers to develop and implement Treatment Plan and Summary Programs within their practices, but will provide us with the unique opportunity of studying the benefits and burdens of the process for both patients and practices.”

Ann H. Partridge, MD, MPH, Chair of the Registry Steering Group and Principal Investigator for the evaluation study
II. Workforce and Professional Development

DIVERSITY IN ONCOLOGY INITIATIVE LAUNCHES
To recruit and retain individuals from populations underrepresented in medicine to cancer careers, ASCO developed the Diversity in Oncology Initiative. The Initiative, funded by Susan G. Komen for the Cure®, consists of three unique awards that offer funding to physicians and medical students with an interest in oncology who self-identify as minorities or who commit to practicing oncology in a medically underserved region of the United States.

Three funding opportunities were created to support the program’s goals.
- The Medical Student Rotation provides 8- to 10-week clinical or clinical research oncology rotations for U.S. medical students from underrepresented populations. Award recipients receive a $5,000 stipend for the rotation plus $1,500 for future travel to the ASCO Annual Meeting and are paired with a mentor.
- The Resident Travel Award provides financial support for residents from underrepresented populations to attend the ASCO Annual Meeting. The award includes a $1,500 travel advance, complimentary meeting registration, and access to the Annual Meeting housing block and ASCO’s travel agency.
- The Loan Repayment Program provides repayment of qualifying educational debt to oncologists or oncology fellows who commit to practicing oncology in a medically underserved region of the United States (designated by the U.S. Health Resources and Services Administration as a Health Professional Shortage Area or Medically Underserved Area). The program will repay up to $35,000 per year for two years (up to $70,000 total) of qualifying education debt.

ASCOSEEKS DATA ON IMPACT OF COLLABORATIVE PRACTICE MODELS
ASCO and the Workforce Advisory Group (WAG) continued to investigate a variety of solutions to the anticipated oncologist workforce shortage in the United States, including collaborative practice models.

Through the ASCO Study of Collaborative Practice Arrangements, funded by Susan G. Komen for the Cure, the Society initiated a study to explore oncology practices’ use of collaborative care teams comprised of varying combinations of oncologists, physician assistants (PAs), and nurse practitioners (NPs).

The oncology profession must include persons with diverse origins and experiences to provide superior patient-centered care for an ever-increasing diverse patient population.
Kenisha Pemberton, Medical Student Rotation participant

People with diverse backgrounds and experiences often bring a unique perspective to patients and their loved ones as they cope with their diagnosis.
Renee Funches, MD, Resident Travel Award recipient

Derrick D. Cox, MD, a surgical oncology fellow at Roswell Park Cancer Institute, became an ASCO member after attending the 2009 Annual Meeting on a Resident Travel Award.
Through a competitive application process, ASCO selected Oncology Metrics in December 2008 as the contractor to collect data for this initiative. This group has extensive experience collecting practice-based data within the oncology community.

Oncology Metrics will:
- Identify existing model practice arrangements that include oncologists, PAs, and NPs and develop metrics to determine the success of these practices in meeting workforce challenges;
- Collect data evaluating the impact of these collaborative practices on the quality and efficiency of care, as well as the satisfaction of the providers and their patients.

The WAG will use these data to formulate solutions that can be adapted for practices with a variety of needs and resources. ASCO expects to complete this project by December 2010.

**ASCO SUPPORTS PROFESSIONAL DEVELOPMENT**

ASCO continues to provide and develop resources to support the career growth of oncologists across the span of time that they practice medicine (from fellowship through active practice). New opportunities in 2009 include:

**ASCO’s Leadership Development Program**

The ASCO Leadership Development Program began in 2009 with 10 participants selected from 138 applications. (The 2010 class will expand to 12.) The year-long program is designed to facilitate early-career oncologists on pathways to become leaders within the Society. Program participants have the opportunity to gain extensive exposure to the mission of ASCO, network with leaders in the organization, better comprehend the Society’s role in improving cancer care and patient welfare, and receive leadership skills training. The first class of program participants will graduate at the 2010 ASCO Annual Meeting in Chicago. Upon completion of the program, graduates will join ASCO’s committees and task forces.

**LEADERSHIP DEVELOPMENT PROGRAM CLASS OF 2009-2010**

*From left to right: Christine H. Chung, MD, Vanderbilt University School of Medicine; Amreen Husain, MD, Stanford University School of Medicine; Gregg E. Franklin, MD, PhD, New Mexico Cancer Center; Dawn L. Hershman, MD, Columbia University Medical Center; Nasser H. Hanna, MD, Indiana University; Jill Gilbert, MD, Vanderbilt University School of Medicine; Matthew D. Galsky, MD, Comprehensive Cancer Centers of Nevada; Anees B. Chagpar, MD, University of Louisville School of Medicine; Quyen Chu, MD, Louisiana State University Health Sciences Center; Jyoti D. Patel, MD, Northwestern University Feinberg School of Medicine.*
ASCO Hosts Oncology Training Program Directors’ Retreat
The first Oncology Training Program Directors’ Retreat—funded by ASCO—provided practical strategies in an interactive format. The Retreat proceedings are posted on ASCO University™. The program was evaluated highly by the 58 participants with support expressed for continued retreats.

Geriatric Issue Exploration Team Forms
Plans made by the Geriatric Issue Exploration Team at their November 2009 meeting will lead to the design of a series of modules on ASCO University that aims to produce a geriatric oncology curriculum for program directors to educate fellows. The development of this curriculum is funded in part by an Association of Specialty Professors grant.

A Continuation of Educational Excellence Maintenance of Certification. The Professional Development Division is on schedule to add two new modules each year on ASCO University for oncologists to use to complete American Board of Internal Medicine (ABIM) Maintenance of Certification requirements for self-assessment of knowledge (Part II). ASCO has launched four modules; in 2008 General Oncology and Cancer Prevention, in 2009 Breast Cancer and Gastrointestinal Cancer.

In-Training Examination. ASCO administered the second annual In-Training Examination at 145 test centers (more than 90% of medical and hematology oncology programs participated) to 1,164 examinees and two program directors on February 24-25, 2009. An Item-Writing Workshop was also conducted at ASCO Headquarters on October 9, 2009.

Methods in Clinical Cancer Research Workshop in Vail. The 2009 ASCO/AACR Vail Workshop provided intensive instruction on designing effective clinical trials to 75 fellows and 25 junior faculty members. The course is partially supported from a National Cancer Institute grant that was approved for five additional years.
The ASCO Cancer Foundation® supports ASCO’s mission of providing the best and most innovative care to patients with cancer by finding the resources to make grants, awards, and education programs possible.

**THE ASCO CANCER FOUNDATION CELEBRATES 10TH ANNIVERSARY**

As the philanthropic affiliate of ASCO, The ASCO Cancer Foundation funds research, education, and cancer care programs both in the United States and abroad. In 2009, the Foundation supported major initiatives including symposia, workshops, enduring educational products, and public forums.

During the 2009 Annual Meeting, the Foundation celebrated its tenth anniversary. During its 10-year history, the Foundation has funded more than $43 million dollars in research grants:
- 406 Young Investigator Awards
- 133 Career Development Awards
- 11 Advanced Clinical Research Awards
- 3 Translational Research Professorships
- 3 Gianni Bonadonna Breast Cancer Research Fellowships
- 6 Community Oncology Research Grants

In March 2009, the Foundation received the highest possible rating of four stars for organizational capacity and efficiency from Charity Navigator, an independent charity evaluator. Ninety one and a half cents of every dollar goes to fund programs like those mentioned above.

**THE FOUNDATION, ASCO RING NYSE® BELL**

The Foundation and ASCO joined the ranks of many notable businesses and organizations by ringing the New York Stock Exchange (NYSE) Closing Bell on August 19, 2009.

The official bell ringing, which is used to signal the start or end of trading for the business day, is a popular marketing platform, offering non-profit organizations like the Foundation and ASCO an opportunity to raise awareness of their mission and work.

Foundation Board of Directors member Lawrence H. Einhorn, MD, rang the bell alongside his patient, Olympic swimmer and testicular cancer survivor Eric Shanteau.

*Left: Amanda Adeleye, of Columbia University, seen here conducting breast cancer research, was awarded the 2009 Medical Student Rotation, which enabled her to complete her oncology rotation at Northwestern University.*

*Photograph by MARK NOVAK*

*Eric Shanteau, Larry Einhorn, MD, and Douglas W. Blayney, MD, (left to right) inspect the NYSE gold medallion that was given to all attendees of the bell ringing.*

*Photograph by DANA MOORE*
Above: from left to right: Larry Norton, MD, George W. Sledge, MD, Eric Shanteau, Richard Adamonis, Senior Vice President Corporate Communications, NYSE Euronext, Douglas W. Blayney, MD, Lawrence H. Einhorn, MD, Richard L. Schilsky, MD, Joseph S. Bailes, MD, Allen S. Lichter, MD, and Nancy R. Daly, MS, MPH, ringing the Closing Bell on August 19, 2009.

Right: New York City Mayor Michael Bloomberg (far left) is presented with the 2009 ASCO Public Service Award.

Ringing the bell at the New York Stock Exchange is something every organization covets and few will achieve. We hope to build off this event to carry our oncology messages to a broad audience throughout the country.

ASCO CEO Allen S. Lichter, MD,
First Chair of the Foundation Board of Directors

At a reception following the bell ringing, the Honorable Michael Bloomberg, Mayor of New York City, was presented with the 2009 ASCO Public Service award.

Other notable speakers at the reception included New York City Council Speaker Christine Quinn and Jane C. Wright, MD, one of the seven founding members of ASCO. In attendance were Foundation Board of Directors sitting members Michael Goldstein, MD; Martin J. Murphy, Jr., MD; Nora Janjan, MD, MPSA; and Sandra Swain, MD; along with Past Chair of the Foundation Board of Directors Larry Norton, MD.

FDA HONORS ASCO FOR COLLABORATIVE ACTIVITIES

ASCO devotes considerable resources to assisting its membership in conducting clinical trials and working with regulatory agencies to develop policies that promote research. The Society partnered with the U.S. Food and Drug Administration (FDA) on its Critical Path Initiative, a national strategy for transforming the way FDA-regulated products are developed, evaluated, manufactured, and used.

ASCO’s work produced recommendations on optimal approaches for development of targeted therapies and design considerations for late-phase clinical trials. The exemplary work produced

"ASCO is proud to work with the FDA to improve clinical trial designs that more effectively and efficiently develop new cancer therapies."

ASCO Immediate Past President Richard L. Schilsky, MD
through Society efforts prompted the FDA to present ASCO with the Commissioner’s Special Citation Award. FDA Commissioner Andrew von Eschenbach, MD, presented the award to ASCO CEO Allen S. Lichter, MD, on December 18, 2008.

The Special Citation Award is a unique honor given as recognition for outstanding and significant public-interest services related to FDA activities.

**THE ASCO CANCER FOUNDATION EXPANDS GRANTS AND AWARDS PROGRAMS**

The ASCO Cancer Foundation Grants and Awards Programs support and encourage excellence in clinical and translational research in the field of oncology.

### Grant Opportunities Available in 2009

**Advanced Clinical Research Awards**

Designed for clinical oncology researchers involved in investigative work for 5-10 years and intended to support original research not currently funded. ACRAS in breast cancer, colorectal cancer, and sarcoma will be awarded in 2010.

**Community Oncology Research Grant**

Intended to support community-based practices to support their efforts to enhance their clinical trials program according to ASCO’s recognized Exemplary Attributes of Clinical Trial Sites (www.ASCO.org/ClinicalTrialResources).

**Comparative Effectiveness Research Professorship, supported by The Breast Cancer Research Foundation**

Intended to provide support to qualified individuals to investigate comparative effectiveness in breast cancer and to train future generations of researchers.

**The ASCO Cancer Foundation Improving Cancer Care Grant, funded by Susan G. Komen for the Cure**

A new grant to support research projects related to the quality of, access to, and delivery of cancer care, with general applicability in breast cancer.

**Young Investigator Award**

Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment.

**Career Development Award**

Provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program.

### New Award Opportunities Available in 2009

**Long-term International Fellowship (LiFe)**

This one- to two-year fellowship for early career oncologists from developing countries to deepen their relationship with an existing mentor in the United States or Canada. The first LiFe Fellowship will be awarded in 2010.

**ASCO Diversity in Oncology Initiative funded by Susan G. Komen for the Cure**

The Diversity in Oncology Initiative is designed to facilitate the recruitment and retention of individuals from populations underrepresented in medicine to cancer careers, with particular attention to the development of clinical practitioners and investigators.

**Established Awards**

**Gianna Bonadonna Breast Cancer Award and Research Fellowship**

This annual award and fellowship recognize outstanding research achievements in breast cancer.

**Merit Award**

Given to oncology fellows who are first authors on abstracts selected for presentation at an ASCO meeting, including the Annual Meeting, the Breast Cancer Symposium, the Gastrointestinal Cancers Symposium, and the Genitourinary Cancers Symposium.

**Clinical Trials Participation Award**

Intended to increase awareness and participation in clinical trials among physicians this award recognizes outstanding community-based research sites.

**International Development and Education Award (IDEA)**

Provided to oncologists in developing countries as a career development and education award.

**ASCO & UICC ICRETT Fellowship**

These scholarships help to facilitate rapid international transfer of cancer research and clinical technology. Each year, ASCO funds 10 UICC International Cancer Technology Transfer Fellowships (ICRETT).

Please see The ASCO Cancer Foundation’s Annual Report for a full listing of 2009 grant and award recipients.
IV. Education

ASCO is committed to supporting the lifelong learning of oncologists by developing resources to enhance the professional development of members across the continuum of their medical education.

**ASCO’S 2009 ANNUAL MEETING FOCUSES ON PERSONALIZING CANCER CARE**

This year’s Annual Meeting focused on the theme of “Personalizing Cancer Care” through a variety of session types and topics. This theme was reflected in the scientific and educational program of the Annual Meeting, with many sessions focused specifically on personalized care in particular disease sites and clinical circumstances, and with faculty who put research results into the context of personalized care.

A Streamlined Experience

ASCO also created ways to help attendees streamline their meeting experience.

- The redesigned online Annual Meeting Itinerary Builder allowed attendees to create an itinerary based on a specific track or build a customized itinerary that could be printed, exported to Microsoft Excel or Outlook, or synched with a smartphone, iPhone, or BlackBerry.
- The General Oncology schedule, introduced in 2008, was composed of sessions selected of interest to the general oncologist and highlighted key scientific findings and educational opportunities across multiple tracks.
- The “Meeting within a Meeting” schedules were offered for hematology, pediatric cancers, gynecologic cancers, central nervous system tumors, and geriatric oncology. Sessions in the identified topic areas were scheduled back-to-back.

A Greener Meeting

ASCO has extended a philosophy of environmental responsibility through many of its programs, and the 2009 Annual Meeting was no exception. The Orange County Convention Center (OCCC) has been nationally recognized for its green initiatives. In 2007, its vigorous recycling program diverted 11,145 tons of material for remanufacture, including 1,200 tons of cardboard and 14 tons of office paper. Only non-oil-based paint products (such as Latex and water-based polyurethanes) and Green Seal™-certified cleaning products are used in the facilities, along with recycled-content bathroom tissue and hand towels. The landscaping around the facility is irrigated with 100% reclaimed water.

Attendees to ASCO’s Annual Meeting saw many pilot environmental projects in place throughout the OCCC, including touch-free hand dryers; low-flow, metering water faucets and waterless urinals in restrooms; and a solar photovoltaic rooftop system, which

‘’Each patient with cancer is different—biologically, clinically, economically, and socially—and a one-size-fits-all approach to treating cancer is not optimal. As oncologists, our focus has always been, and must remain, treating the patient, not the disease. We must each acquire the skills and make the commitment to do so in the optimal way.’’

Richard L. Schilsky, MD, Immediate ASCO Past President

PHOTOGRAPH BY ZACH BOYDEN-HOLMES

ASCO recycled 175 tons of waste during the 2009 Annual Meeting.
converts solar radiation into direct current electricity. To support these green projects, ASCO provided recycling areas near tote bag pickup and shuttle drop-off locations. Attendees were encouraged to recycle any Meeting materials they did not want at these stations.

There will be more green initiatives from ASCO in the coming year:
- Tote bags will be made of recycled material.
- Water stations will be placed in meeting rooms, replacing bottled water.
- “Green” tables will be located throughout the convention center for recycling meeting materials.

The convenience of this content underscores the concept of ASCO University serving as an educational home for oncology care professionals.

Jamie Von Roenn, MD

Fellows Lounge at Annual Meeting
ASCO supports its associate and active junior members through the Fellows’ Lounge at Annual Meeting. Lounge attendance increased from 567 attendees in 2007 to 1,105 attendees in 2008 and even more to 1,250 attendees in 2009.

ASCO UNIVERSITY LAUNCHES NEW MODULES
ASCO’s eLearning center, ASCO University encourages lifelong learning by offering practice resources and educational opportunities to those within all subspecialties of oncology. It is also a key support for those enrolled in Maintenance of Certification (MOC) and those preparing for Certification.

ASCO University promotes continuity among subspecialty-specific products and services so that all users may share a similar understanding about treatment and best practices. Areas of the site include:
- Modules using a case-based approach with opportunities for self-assessment that address real needs of the oncology community
- Modules, MOC content, and educational items that concisely target specific topics
- OnDemand content including modules and links to ASCO Virtual Meeting and Podcast content
- Support for fellows

ASCO plans to add more content for the future including:
- Quarterly Journal of Clinical Oncology (JCO) Reviews
- Slide Library
- Seminal article and core content library
- More opportunities for MOC
- A new edition of ASCO-SEP®
ASCW HOSTS ELECTRONIC HEALTH RECORDS SYMPOSIUM

With the American Recovery and Reinvestment Act (ARRA) signed into law, 2009 was an excellent time to implement Electronic Health Records (EHR) into practice. ASCW hosted its second EHR Symposium: Harnessing the EHR, From Incentives to Sustainability. The Symposium offered resources and information needed to make informed decisions on the selection, adoption, and use of EHR technologies.

THEMATIC AND CO-SPONSORED MEETINGS IN 2009

ASCO’s array of educational and scientific programs serves the diverse professional needs and interests of its growing membership and oncology practitioners worldwide.

Best of ASCW

The Best of ASCW® meetings are designed to update oncologists on the latest research and findings that are presented at the ASCW Annual Meeting.

The 2009 Best of ASCW® meetings took place in Los Angeles, California and Atlanta, Georgia in 2009. Best of ASCW® International meetings took place for the first time in Australia, China, France, and Slovakia in 2009. In addition, Best of ASCW International meetings took place in the following repeat locations:

- Brazil
- Japan
- Mexico
- Singapore
- India
- Lebanon
- Panama

News from the 2009 Thematic and Co-Sponsored Meetings

Gastrointestinal Cancers Symposium

In advance of the Gastrointestinal Cancers Symposium ASCW released its first Provisional Clinical Opinion (PCO) on the use of KRAS gene mutation testing in patients with metastatic colorectal cancer to guide treatment with the anti-EFGR monoclonal antibodies cetuximab and panitumumab.

An economic analysis showed that routine testing for KRAS gene mutations in patients with metastatic colorectal cancer could save the U.S. health system up to $604 million per year in the cost of the drug cetuximab. This study coincided with the release of ASCW’s provisional clinical opinion recommending that all patients with metastatic colorectal cancer who are candidates for anti-EFGR therapy have their tumors tested for KRAS gene mutations.

Co-sponsors of the meeting: ASCW, the American Gastroenterological Association Institute, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO).

Abstracts

- Total number of abstracts submitted: 563
- 471 abstracts were selected for poster presentation
- 32 were selected for oral presentation
- The top 25 abstracts submitted by physicians or researchers in training received Merit Awards

Total Number of Attendees: 2,925
Genitourinary Symposium

A joint guideline was issued on the first day of the Genitourinary Cancers Symposium by ASCO and the American Urological Association (AUA) that recommends that healthy men, who are screened regularly for prostate cancer and show no symptoms of the disease, talk to their doctors about using a 5-alpha reductase inhibitor (5-ARI) to prevent the disease.

Co-sponsors of the meeting: ASCO, the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO).

Breast Cancer Symposium

The Breast Cancer Symposium featured results from two potentially practice-changing studies:

- A large, retrospective study showing that nearly three-quarters of breast cancer deaths occur among the minority of women who do not undergo regular screening mammograms.
- A study showed that vitamin D deficiency is prevalent in women being treated for breast cancer.

Co-sponsors of this meeting: American Society of Breast Disease, The American Society of Breast Surgeons, ASCO, the American Society for Radiation Oncology, the National Consortium of Breast Centers, and The Society of Surgical Oncology.

DOMESTIC AND INTERNATIONAL MEETING ATTENDEE PERCENTAGES

- Annual Meeting, Orlando
- Best of ASCO–Atlanta
- Best of ASCO–Los Angeles
- Breast Symposium, San Francisco
- ASCO/COG Symposium, Dallas
- Electronic Health Records, San Francisco
- GI Symposium, San Francisco
- GIU Symposium, Orlando

0 20% 40% 60% 80% 100%

Domestic  International
INTERNATIONAL MEETINGS, COLLABORATIONS IN 2009

ASCO Expands Multidisciplinary Cancer Management Courses
In 2009, ASCO enhanced the impact and scope of the Multidisciplinary Cancer Management Course (MCMC) program. With its partner in Nepal, ASCO piloted an improved needs assessment process to better understand challenges and learning needs specific to the local practice environment. ASCO also developed MCMC “Train the Trainer” module designed to teach methods and practical skills for course implementation.

Advanced Cancer Courses
ASCO’s international Advanced Cancer Courses are held outside the United States with national and regional partners and cover a single topic in-depth, often incorporating ASCO educational products and resources. In 2009, two new courses were offered for the first time internationally.

ASCO International Clinical Trials Workshop
The first International Clinical Trials Workshop was held in Buenos Aires, Argentina. ASCO partnered with the Latin American and Caribbean Society of Medical Oncology (SLACOM) and the National Cancer Institute to deliver best practices training in clinical trial design and implementation.

EPEC™-O Palliative Care Course
The first Advanced Cancer Course on Palliative Care was held in Cairo, Egypt. ASCO partnered with the South and East Mediterranean College of Oncology (SEMCO) and experts from the Institute for Palliative Medicine in San Diego, the National Cancer Institute and the Open Society Institute to conduct the workshop, which was based on the Palliative and End-of-Life Care for Oncology (EPEC™-O) curriculum.

International Cancer Corps
ASCO has partnered with Health Volunteers Overseas (HVO) to launch a new humanitarian program, the International Cancer Corps (ICC). The ICC will enable ASCO members to volunteer their time to teach in medical facilities in developing countries.

Medical Oncology Training Logbook for Global Core Curriculum
Since 2004 when ASCO and ESMO issued their joint Recommendations for a Global Curriculum in Medical Oncology, the two societies have worked closely to promote the adoption of the recommendations in countries around the world, achieving successes in the international standardization of training in this subspecialty. In 2009, the ASCO-ESMO Task Force released a Log Book—a record of oncology trainees’ educational program and their progress through the curriculum components—as a supplemental tool to the curriculum.

IDEA—American Cancer Society University Educational Collaboration
Through its International Development and Education Award (IDEA) program, ASCO and the Foundation support the professional development of young oncologists in developing countries. Through its ACS University program, the American Cancer Society (ACS) trains leaders from developing countries in advocacy, organizational development, and public education. In 2009, ASCO and ACS linked these two programs to deliver ACSU advocacy training to 20 IDEA recipients at the 2009 Annual Meeting.
V. Publications

**JOURNAL OF CLINICAL ONCOLOGY PUBLISHES ITS 500TH ISSUE**

The *Journal of Clinical Oncology* (JCO) published its 500th issue in November. From its start as a monthly publication in 1983 with a circulation under 5,000, JCO now publishes three issues per month and has a circulation of over 25,000, plus a monthly online readership of more than 180,000 unique visitors.

**JCO IMPACT FACTOR INCREASES**

The JCO Impact Factor increased for a fourth consecutive year, as reported by Thomson Reuters in its 2008 Journal Citation Report. The impact factor represents a mean of the number of papers published during two years, divided by the total number of citations in the following year. Last year, 766 of JCO’s articles published in 2006 and 2007 were cited at least once, for a total of 97,639 citations—a 20% increase from the previous year, according to the report. The rise in the impact factor of nearly 50% since 2005 is unprecedented.

By impact factor, the publication ranks:
- Fourth of 144 oncology journals tracked worldwide
- Forty-first among all scientific journals surveyed, putting it in the top 1% of all science, technology, and medical publications
- Second in number of citations among oncology journals, and 25th among all 6,598 scientific journals monitored

**JOURNAL OF ONCOLOGY PRACTICE EXPLORES THE COST OF CANCER CARE**

The cost of medical care in the United States is a critical subject for many Americans and a topic of concern within governmental, academic, and industry groups. Costs associated with treatments for cancer are of particular interest, since they tend to be much higher than those associated with treating other diseases.

Drug costs are generally a greater proportion of the total cost burden for patients with cancer than for patients with other diseases. Additionally, the benefits of using those drugs are not seen in every patient; to help a small number of patients realize benefit from these drugs, oncologists must treat a larger number of patients. The September 2009 issue of the *Journal of Oncology Practice* (JOP) focused on the cost of cancer care and provided important insights into this complex situation.
ASC PUBLISHES 5TH EDITION OF PRACTICAL TIPS FOR THE ONCOLOGY PRACTICE

ASC published the 5th edition of Practical Tips for the Oncology Practice. This comprehensive resource provides up-to-date information about coding, billing, and Medicare coverage for oncology services and the regulatory policies affecting the day-to-day practice of oncology.

2009 ASCO DAILY NEWS EXPANDED COVERAGE

Under the continued leadership of Editor in Chief Monica Morrow, MD, and Associate Editor John Sweetenham, MD, the 2009 edition of ASCO Daily News featured new content in the form of Expert Editorials with international perspectives and coverage of the interactive Clinical Problems in Oncology sessions. For the second year, a Japanese translation was made available to attendees.

ASC NEWS & FORUM PUBLISHES MEMBERSHIP SERIES

To help members take advantage of the countless benefits that ASCO offers, ASCO News & Forum launched a new series that highlights member benefits available to each membership category and outlines the value you receive with ASCO membership.

- Complimentary educational products and resources from the ASCO Annual Meeting, including the Annual Meeting Proceedings and the Annual Meeting Educational Book on CD
- Discounted registration rates for the Annual Meeting and co-sponsored symposia
- Opportunities for networking with colleagues in the oncology community.
ASCO MEMBERSHIP

ASCO represents oncology professionals from all disciplines, subspecialties, and practice sites. The current membership consists of 28,181 domestic and international professionals. The Society serves members functioning in many fields, including medical oncology, hematology, radiation oncology, surgical oncology, gynecologic oncology, pediatric oncology, and oncology nursing.

ASCO’s membership is broken down into seven membership categories: Active, Active-Junior, Associate, Active-Allied, Affiliate, International Corresponding, and Emeritus. Above is a chart displaying the composition of membership and a description of each membership category.

Active
Available to experienced licensed physicians or other health professionals of any nation who devote a majority of their professional activity to cancer patient care and/or research or education in the biology, diagnosis, prevention or treatment of human cancer.

Active-Junior
Available to physicians during the first three years after completion of an approved oncology subspecialty training program and who qualify for Active Membership.

Associate
Available to health professionals having an MD, DO, PhD, PharmD, or other doctoral degree, who are participating in a subspecialty training program in oncology or another field that would lead to eligibility for Active or Active-Allied membership.

Active-Allied
Available to health professionals at the doctoral level (e.g., epidemiologists, biostatisticians, public health specialists, nurses, other scientists, etc.) or individuals with equivalent academic ranks who are not eligible for Active Membership and who have a predominant interest in the biology, diagnosis, prevention or treatment of human cancer (e.g., radiologists, pathologists, nuclear medicine physicians, pharmacologists, researchers, etc.).

Affiliate
Available to oncology nurses, nurse practitioners, physician assistants, practice management professionals and other health specialists who devote a majority of their professional activity to the care and treatment of patients with cancer. Membership shall be limited to those personnel who function as integral members of a team of oncologists responsible for the care of such patients or who engage in the conduct of clinical trials. Also available to individuals who hold leadership positions or have taken a distinguished leadership role in a nationally or internationally recognized not-for-profit, tax-exempt organization dedicated to cancer patient advocacy or survivorship.

International Corresponding
Available to experienced physicians who are eligible for Active Membership and who reside in a developing country designated by the World Bank as “Low Income,” “Lower-Middle Income” or “Upper-Middle Income.” Those that reside in eligible countries and who meet these requirements have the option of applying for Active membership or International Corresponding membership.

In 2009 the Board expanded the geographic eligibility for International Corresponding Membership beginning with the January 1, 2010 new member induction date. Eligibility will now be determined using the World Bank’s list of developing countries and introduces a tiered dues structure. As a result, clinicians in many previously ineligible countries with some of the world’s largest populations of patients with cancer, such as India, China, and Egypt, now have this ASCO membership category available to them.

Emeritus
Available to Active, Active-Allied, International Corresponding and Affiliate members who are 65 years or older or retired. Also available to Active, Active-Allied, International Corresponding and Affiliate members who are permanently disabled.
VI. ASCO’s Multimedia Collection
ASCO.ORG: THE VOICE OF ONCOLOGY ONLINE
The explosive growth of oncology data and research online, coupled with the increased speed and functionality of the Web, has enabled ASCO to dramatically improve its primary online resource for oncologists, ASCO.org. The website’s mission is to be the “voice of oncology on the Internet,” and with the addition of a highly customizable interface, the new ASCO.org is well positioned as the authoritative voice of oncology online.

SOCIAL NETWORKING
Web 2.0 aims to increase dialogue, create communities of people with shared interests, and facilitate the use of enhanced technology, such as video posts, and is a new area for ASCO. Although Society-vetted content will remain a cornerstone of ASCO’s leadership in clinical oncology information, implementation of these new, user-driven technologies should keep the Society at the cutting edge of information management and dissemination. Patients and the improvement in their cancer care remain the driving force of ASCO’s efforts across a broad spectrum of activities. To achieve these goals in the Web 2.0 world, ASCO has become active on social networking sites such as Facebook and Twitter. Also, a members-only group on Linked In has facilitated discussion and networking among ASCO-affiliated oncology professionals.

Social networking sites (the most recognizable are Facebook and Linked In) allow participants with common interests to post their ideas along with pictures, videos, and hypertext links. ASCO launched several social networking sites to enable oncologists to connect with peers, exchange ideas, and share best practices. On the Oncology EHR site, practice staff and electronic health record (EHR) vendors share their experiences with EHR products through blogs and forums.
VIRTUAL MEETING UPGRADES
ASCO’s Virtual Meeting (www.asco.org/vm), the most comprehensive collection of oncology-related multimedia lectures on the Web, was upgraded to run using Adobe Flash and Microsoft Silverlight. Both web browser plug-ins enable animation and audio-video playback characterized in rich Internet applications. The new player includes a “Top Videos” section, as well as a “Related Content” section.

PODCASTS
Starting with the 2009 Gastrointestinal Symposium podcast subscription, members are able to download the complete audio and video podcast libraries (www.asco.org/podcast) of the latest oncology research from all captured thematic symposia and Annual Meeting sessions. Podcasts offer subscribers the flexibility to revisit content from previously attended sessions and catch up on unattended ASCO events.

ASCO TV
ASCO TV is ASCO’s own broadcast network at the ASCO Annual Meeting. The ASCO TV program encompasses replay and live broadcasts of sessions, as well as specially designed features, which appeared on TV monitors throughout the convention center, as well as on all shuttle busses and selected hotels during the 2009 Annual Meeting. Monitors were located at public areas around the convention center, including food areas, high-traffic, and waiting areas.
VII. Resources to Share with Patients
ASCO provides an array of oncologist-approved resources to share with patients, colleagues, and the public. ASCO’s patient education and promotional materials can now be ordered directly through the ASCO Bookstore on ASCO.org. Beginning in October, ASCO began charging a small fee for the ASCO Answers Fact Sheets and Cancer.Net Guides to Cancer. The price offsets the production costs and allows the Society to continue to develop and distribute additional patient information materials covering topics of interest to people with cancer and their families. There is no charge for the booklets “Cancer in Older Adults” or “Managing the Cost of Cancer Care.” Cancer.Net promotional materials, including referral cards, leaflets, cancer information prescription pads, and posters are also available through the Bookstore at no charge.

All patient information materials are supported by The ASCO Cancer Foundation®. Electronic versions of all of these materials are also provided on Cancer.Net.

CANCER.NET RELAUNCHES
ASCO relaunched its patient information website, Cancer.Net (www.cancer.net), with a new design. Cancer.Net brings the expertise and resources of ASCO, the voice of the world’s cancer physicians, to people living with cancer and those who care for and care about them.

The new Cancer.Net homepage has three distinct areas to highlight content, such as the Find an Oncologist database, news from ASCO meetings and journals, videos from ASCO experts, podcasts, and weekly feature articles.

The importance of visual elements in the new design is demonstrated with new icons in the cancer type sections that represent different parts of the articles. Also, Cancer.Net visitors can now share the information they find with their family and friends using the “Bookmark and Share” tool to send the link in an e-mail or post it to Facebook or Twitter.

CANCER ADVANCES: NEWS FOR PATIENTS FROM ASCO MEETINGS
Cancer Advances helps inform patients about the latest news and advances in cancer research from the ASCO Annual Meeting, Breast Cancer Symposium, Gastrointestinal Symposium, and Genitourinary Symposium. In addition to clinical research summaries, the newsletter explains how each finding relates to cancer care in a section called “What This Means for Patients.”

The publications are available at www.cancer.net/canceradvances.

ASCO PATIENT GUIDES HELP PATIENTS UNDERSTAND ASCO CLINICAL PRACTICE GUIDELINES
ASCO patient guides are easy-to-read summaries based on ASCO Clinical Practice Guidelines that provide a patient-oriented view of the guidelines. Guides released in 2009 include:

- What to Know: ASCO’s Guideline on Drugs to Lower Breast Cancer Risk

  In 2002, ASCO updated a clinical practice guideline from 1999 on the use of drugs to help lower the risk of breast cancer. This guideline was expanded again in 2009 to update the recommendations for the drug raloxifene as a way to lower the risk of breast cancer for some women.

- What to Know: ASCO’s Guideline on 5-alpha Reductase Inhibitors for Prostate Cancer Prevention

  A patient guide based on recommendations developed by ASCO and the American Urological Association (AUA) for the use of 5-ARIs to help lower the risk of prostate cancer in men.
ASCO RAISES AWARENESS THROUGH FIGURE SKATING EVENTS

ASCO and U.S. Figure Skating, the sport’s national governing body, worked with current skaters and past champions in support of their efforts in the fight against cancer. The year-long partnership that began in October 2009 provided ASCO with a unique opportunity to reach the public with vital information from Cancer.Net. Cancer.Net served as the title sponsor of the 2009 Skate America—U.S. Figure Skating’s premier annual international event that took place Nov. 13-15 in Lake Placid, New York.

In addition, Kaleidoscope, a televised cancer awareness event, aired on Thanksgiving Day on FOX immediately following the traditional football game. Kaleidoscope combined the beauty of skating, the excitement of song, and the message of survivorship to raise awareness of the key issues surrounding women and cancer. Cancer.Net served as the official clinical cancer information resource for the event.
VIII. Leadership

The development of the educational and scientific programs in support of ASCO’s mission is a monumental task, and one that would not be possible without the hard work and dedication of the hundreds of leaders, committee members, and volunteers who commit their time and considerable talent.
ASCO STATESMAN AWARDS HONOR MEMBERS FOR EXCEPTIONAL SERVICE

Many members donate their time and leadership abilities to the Society each year, ensuring that ASCO can continue to represent the interests of oncologists and their patients, as well as pursue an active role in improving cancer care worldwide. This year, ASCO recognized five of these dedicated volunteers by presenting them with the ASCO Statesman Award.

The Statesman Award was created in 2007 as a way to recognize the voluntary efforts of ASCO members who benefit the Society, the specialty of oncology, and patients with cancer.

The 2009 ASCO Statesman Award Winners

Gabriel N. Hortobagyi, MD, FACP
M. D. Anderson Cancer Center

Scott M. Lippman, MD
M. D. Anderson Cancer Center

Barbara L. McAneny, MD
New Mexico Oncology Hematology Consults, Ltd.

Monica Morrow, MD
Memorial Sloan-Kettering Cancer Center

Jamie H. Von Roenn, MD
Northwestern University
ASCOCOMMITTEES

ASCO thanks the many volunteers who serve on the committees. Their time, dedication, and hard work support the Society’s governance and the fulfillment of the ASCO mission.

Bylaws Committee
Joseph DiBenedetto Jr., MD, Chair

Cancer Communications Committee
Nicholas J. Petrelli, MD, Chair

Cancer Education Committee
Kim Allyson Margolin, MD, Chair

Cancer Prevention Committee
Victor G. Vogel, MD, Chair

Cancer Research Committee
Carolyn D. Runowicz, MD, Chair

Clinical Practice Committee
Michael N. Neuss, MD, Chair

Clinical Practice Guidelines Committee
Sandra L. Wong MD, MS, Chair

Ethics Committee
Daniel Malin Hayes, MD, Chair

Government Relations Committee
Joseph Bailes, MD, Chair

The ASCO Cancer Foundation Grants Selection Committee
Lillian Siu, MD, Chair

Integrated Technology Committee
L. Michael Glodé, MD, FACP, Chair

International Affairs Committee
Eliezer Robinson, MD, Chair

Membership Committee
Leon Harold Dragon, MD, Chair

Nominating Committee
Karen Kelly, MD, Chair

Professional Development Committee
Robert J. Mayer, MD, Chair

Publications Committee
Julie Vose, MD, Chair

Quality of Care Committee
Samuel M. Silver, MD, PhD, FACP, Chair

Scientific Program Committee
Daniel F. Hayes, MD, Chair

Special Awards Selection Committee
Richard L. Schilsky, MD, Chair

TASK FORCES AND ADVISORY COMMITTEES

Task Force on Cost of Care
Lowell Schnipper, MD, Chair

Health Disparities Advisory Group
Lisa Newman, MD, Co-Chair
Otis Brawley, MD, Co-Chair

Workforce Advisory Group
Dean F. Bajorin, MD, Co-Chair
Michael Goldstein, MD, Co-Chair

2009 EXECUTIVE LEADERSHIP AND DEPARTMENT DIRECTORS*

Chief Executive Officer
Allen S. Lichter, MD

Vice President and General Counsel
Dina Michels, Esq.

Cancer Policy and Clinical Affairs
Deborah Karmin, PhD, Senior Director
Mark Somerfield, PhD, Director
Shelagh Foster, Director
Karen Hagerty, MD, Director
Kristen McNiff, MPH, Director
Suanna Bruinooge, Director

Communications and Patient Information
Kristin A. Ludwig, APA, Senior Director
Laura Livingston, Director
Lynne Blasi, Director

Education, Science, and Professional Development
Cara Molinari, Senior Director
Marilyn J. Raymond, PT, PhD, Director

Finance and Administration
Paul Aines, CPA, Senior Director
Patricia Page, Director

Human Resources
Kay Noll, Senior Director

International Affairs
Doug Pyle, Senior Director

Integrated Media and Technology
Bernie Khoo, Senior Director
Lisa Greaves, Director
Allen Hassani, Director
Lisa Johnson, Director
Narges Khodaei, Director

*As of November 13, 2009

36 2009 ANNUAL REPORT
ASCO Statement of Revenues and Expenses

<table>
<thead>
<tr>
<th>OPERATING REVENUES</th>
<th>FY 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dues and Subscriptions</td>
<td>13,956,620</td>
</tr>
<tr>
<td>Meetings</td>
<td>29,202,775</td>
</tr>
<tr>
<td>Publications</td>
<td>24,036,954</td>
</tr>
<tr>
<td>Contributions</td>
<td>8,669,741</td>
</tr>
<tr>
<td>Investment Income</td>
<td>1,784,672</td>
</tr>
<tr>
<td><strong>Total Operating Revenues</strong></td>
<td><strong>77,650,762</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPERATING EXPENSES</th>
<th>Program:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member &amp; Meeting Services</td>
<td>14,373,926</td>
</tr>
<tr>
<td>Publishing</td>
<td>13,945,658</td>
</tr>
<tr>
<td>Integrated Media &amp; Technology</td>
<td>9,285,407</td>
</tr>
<tr>
<td>Cancer Policy and Clinical Affairs</td>
<td>8,282,511</td>
</tr>
<tr>
<td>Education, Science, Prof Dev.</td>
<td>5,052,675</td>
</tr>
<tr>
<td>Communications and Patient Information</td>
<td>4,833,210</td>
</tr>
<tr>
<td>International Affairs</td>
<td>1,051,989</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td><strong>69,780,942</strong></td>
</tr>
</tbody>
</table>

| Operating Surplus/(Deficit) | 7,869,820 |
| Long Term Investment | 9,786,645 |
| Unrealized Gain/(Loss) Bond | 9,342,942 |
| **Change in Unrestricted Net Assets** | **26,999,407** |
| Net Assets Beginning of the Year | **22,400,477** |
| Net Assets End of the Year | **49,399,884** |

**REVENUES**
- Dues and Subscriptions
- Meetings
- Publications
- Contributions
- Investment Income

**EXPENSES**
- Programs
- Administration
- Meeting
Supporter Acknowledgment

The American Society of Clinical Oncology and The ASCO Cancer Foundation® gratefully acknowledge the following individuals and organizations for their support.

**INDIVIDUALS**

*Gifts received from January 1–December 21, 2009*

**Gifts exceeding $1,000**

- Joseph S. Bailes, MD
- Dean F. Bajorin, MD
- Edward Paul Balaban, MD
- Thomas M. Beck, MD
- Monica M. Bertagnolli, MD
- Joseph R. Bertino, MD
- Douglas W. Blayney, MD
- Clara D. Bloomfield, MD
- Gennady Bratslavsky, MD
- Kenneth H. Buetow, PhD
- Paul A. Bunn, Jr., MD
- Howard A. Burris, III, MD
- Terry S. Coleman, JD
- Barbara Conley, MD
- Charles L. Conlon, MD
- Nancy Riese Daly, MS

**Gifts up to $1,000**

- Janet Dancey, MD
- Angelo Di Leo, MD, PhD
- Carol Doyle-Clarke
- Leon H. Dragon, MD
- Mark Dudley, PhD
- Lawrence H. Einhorn, MD
- Ezekiel J. Emanuel, MD, PhD
- Masakazu Fukushima, PhD
- Gwen A. Fyle, MD
- Suzanne George, MD
- Mark Green, MD
- Stephen Grubbs, MD
- Stephen H. Grund, MD, PhD
- Rajashree Gudi, MD, FACP
- James L. Gulley, MD, PhD, FACP
- Dr. & Mrs. Denis B. Hammond, MD
- Daniel F. Hayes, MD
- Harry W. Herr, MD
- Gabriel N. Hortobagyi, MD, FACP
- Clifford A. Hudis, MD
- Susan Hugheson
- Lowell F. Inhorn, MD
- S. Ivy, MD
- Joseph O. Jacobson, MD
- David H. Johnson, MD, FACP
- C. Michael Jones, MD, FACP
- Marcos Joppe, MD, FACP
- Deborah Kamin, PhD
- Jennifer C. King, PhD
- Barnett Kramer, MD, MPH
- Mark J. Krasna, MD
- Van L. Lackey, MD
- Robert M. Langdon, Jr., MD, FACP
- Theodore Steven Lawrence, MD, PhD
- Allen S. Lichter, MD, and Evie Lichter
- Katherine Y. Look, MD
- Patricia LaRusso, DO
- Gary H. Lyman, MD
- Mitchell Machtay, MD
- Benjamin T. Marchello, MD
- Kim Margolin, MD
- Thomas A. Marsland, MD
- Marilyn N. Matthies
- Robert J. Mayer, MD
- D. McMeekin, MD
- Robert S. Miller, MD
- I. Monica Minkoff, MD
- Monica Morrow, MD
- Mir M. Mousavi, MD
- Therese M. Mulvey, MD
- Martin J. Murphy, Jr., PhD, DMedSc, and Ann Murphy, PhD
- Hyman Bernard Muss, MD
- Michael N. Neuss, MD, and Gwyneth J. Neuss
- Susan O’Brien, MD
- Mark S. Pascal, MD
- William Charles Penley, MD
- Michael C. Perry, MD
- Joseph L. Potz, MD
- Kathleen I. Pritchard, MD, FRACP
- Barbara Pro, MD
- Kenneth Roop Rai, MD
- Gregory H. Reaman, MD
- Bryce Reeve, PhD
- Gerald John Robbins, MD
- Bruce J. Roth, MD
- Carolyn D. Runowicz, MD
- John Sandlund, MD
- Richard L. Schilske, MD
- Laura S. Schmidt, PhD
- David F. Sciotorto, MD, and Katie Sciotorto
- Frances A. Shepherd, MD
- Richard Simon, MD, ScD
- Lillian Siu, MD
- George W. Sledge, MD
- Enrico Calisto Sobong, MD
- Lawrence Salin, MD, FACP, FASTRO
- Sandra M. Swain, MD
- The Estate of Sandra Sym
- Joel E. Tepper, MD
- David Thomas, PhD
- Peter M. Townley, MD, FACP
- Michael B. Troner, MD
- Everett E. Vokes, MD
- Jamie Von Roenn, MD
- K. Robin Yabroff, PhD, MBA
- Peter P. Yu, MD
- Robin Zor, MD, FACP

**Gifts up to $1,000**

- Anonymous
- James L. Abbazese, MD
- Joann R. Ackler, RN, OCN
- F. E. K. Addo, MD
- Dennis and Carol Ahnen
- Paul A. Aines
- Kathy S. Albain, MD
- Vincent Albo, MD, and Kathryn Albo
- Afasar Ali
- Michael S. Allen
- Kenneth Alonso, MD
- Ali S. Al-Shanqeeti, MD
- Joash R. Aluoch, MD, PhD, FRCP
THE ASCO CANCER FOUNDATION NOTES WITH REVERENCE THE INDIVIDUALS MEMORIALIZED BY OUR DONORS.

A Cancer Sufferer
Martin D. Abelloff, MD
Cheryl Alexander
Barry Axelrad
Zenaida V. Bonaticla
Robert F. Bernhard
Robert Beyrerlein
Tom Bruch
Harold Carey
Christopher A. Clarke
Stuart A. Cohen
Christine L. Couch
Joyce Cruse
Jack Dadaian, MD
Joseph M. Dickler
Jack Dadaian, MD
Joyce Cruse
Christine L. Couch
Stuart A. Cohen
Christopher A. Clarke
Harold Carey
Alexander Zukiwski, MD
Robert J. Zullo, MD
Alexander Zukiwski, MD
Robert J. Zullo, MD
THE ASCO CANCER FOUNDATION JOINS IN CELEBRATING THE INDIVIDUALS HONORED BY OUR DONORS.
NON-PROFIT ORGANIZATIONS

Gifts exceeding $1,000
American Association for Cancer Research
American Cancer Society
ASCO and The ASCO Cancer Foundation Board Of Directors
ASCO Clinical Practice Committee Association of Community Cancer Centers
Association of Specialty Professors
Astellas USA Foundation
BikeTexas Education Fund
Bradley Stuart Beller Fund
Coalition of Cancer Cooperative Groups
Connecticut Oncology Association
Don Shula Foundation, Inc.
Ewa Maria Kukrika Fund for Pancreatic Cancer Research
Indiana Medical Oncology Society
Journal of Clinical Oncology
Kidney Cancer Association
McHenry and Lisa Tichenor Fund of Communities Foundation of Texas Medical Oncology Association of Southern California, Inc.
Michigan Society of Hematology and Oncology
Milton and Miriam Waldbaum Family Foundation
Mississippi Society of Oncology
National Coalition of Cancer Survivorship
National Comprehensive Cancer Network
New York State Society of Medical Oncologists & Hematologists
Northern New England Clinical Oncology Society
Oregon Society of Medical Oncology, Inc.
Prevent Cancer Foundation
Robin Hood MD Good Works
Sarah Cannon Research Institute
Sarcoma Foundation of America
Susan G. Komen for the Cure
The Breast Cancer Research Foundation
The Weinstein Family Charitable Fund
Schwab Charitable Fund
Society of Rhode Island Oncologists
Stonebridge Women’s Club
The Community Foundation for Greater Atlanta
The Nieman Charitable Foundation, Inc.
The Weinstein Family Charitable Fund
U.S. Figure Skating

Gifts up to $1,000
Alpine Hematology-Oncology
Celtic Pines Services Inc.
Chatanooga Oncology & Hematology Associates, P.C.
Florida Cancer Specialists
George Washington University
H.B. Stubbs Company, LLC - East
Health Options
Iowa Cancer Specialists, P.C.
Jamestown Medical Oncology
Hematology, LLC
Leerink Swann, LLC
Medical Marketing Studies U.S., Inc.
Newland Medical Associates, P.C.
Onyx Pharmaceuticals, Inc.
Pharmaceuticals, Inc.
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM

Gifts up to $1,000
Action to Cure Kidney Cancer
American Society of Clinical Oncology
Arnoldus Goudsmit, MD, ASCO Founder Fund
Bishop Kelly High School
District of Columbia Philanthropic Educational Organization
Network For Good

CORPORATIONS

Gifts exceeding $1,000
Abraxis Oncology
Agen
Aptium Oncology
ARIAD Pharmaceuticals, Inc.
AstraZeneca
Bayer Healthcare Pharmaceuticals
Biogen IDEC
B-Line Diner
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
Capriccio Grill
Celgene Corporation
Centocor Ortho Biotech Inc.
Clinical Care Options
Curatio CME Institute
Dendreon Corporation
Educational Concepts Group, LLC
Eisai Inc.
EMD Serono, Inc., an affiliate of Merck KGaA
Enzon Pharmaceuticals
Fidelity Charitable Gift Fund
GE Healthcare
Genentech BioOncology™
Genomic Health, Inc.
Genzyme
GloxSmithKline Oncology
Haymarket Medical
ImClone Systems Incorporated
Interactive Network for Continuing Education
Lilly USA, LLC
Louisiana Oncology Associates, PMC
Merck Oncology
Millenium: The Takeda Oncology Company
Myriad Genetics Laboratories, Inc.
Nebraska Cancer Specialists
Novartis Oncology
Onyx Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc.
Pebadby Orlando
Pfizer Oncology
Pharmasset Development Group
Physicians Education Resource
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM

Gifts up to $1,000
Alpine Hematology-Oncology
Celtic Pines Services Inc.
Chatanooga Oncology & Hematology Associates, P.C.
Florida Cancer Specialists
George Washington University
H.B. Stubbs Company, LLC - East
Health Options
Iowa Cancer Specialists, P.C.
Jamestown Medical Oncology
Hematology, LLC
Leerink Swann, LLC
Medical Marketing Studies U.S., Inc.
Newland Medical Associates, P.C.
Onyx Pharmaceuticals, Inc.
Pharmaceuticals, Inc.
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM

Gifts up to $1,000
Alpine Hematology-Oncology
Celtic Pines Services Inc.
Chatanooga Oncology & Hematology Associates, P.C.
Florida Cancer Specialists
George Washington University
H.B. Stubbs Company, LLC - East
Health Options
Iowa Cancer Specialists, P.C.
Jamestown Medical Oncology
Hematology, LLC
Leerink Swann, LLC
Medical Marketing Studies U.S., Inc.
Newland Medical Associates, P.C.
Onyx Pharmaceuticals, Inc.
Pharmaceuticals, Inc.
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM

Gifts up to $1,000
Alpine Hematology-Oncology
Celtic Pines Services Inc.
Chatanooga Oncology & Hematology Associates, P.C.
Florida Cancer Specialists
George Washington University
H.B. Stubbs Company, LLC - East
Health Options
Iowa Cancer Specialists, P.C.
Jamestown Medical Oncology
Hematology, LLC
Leerink Swann, LLC
Medical Marketing Studies U.S., Inc.
Newland Medical Associates, P.C.
Onyx Pharmaceuticals, Inc.
Pharmaceuticals, Inc.
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM

Gifts up to $1,000
Alpine Hematology-Oncology
Celtic Pines Services Inc.
Chatanooga Oncology & Hematology Associates, P.C.
Florida Cancer Specialists
George Washington University
H.B. Stubbs Company, LLC - East
Health Options
Iowa Cancer Specialists, P.C.
Jamestown Medical Oncology
Hematology, LLC
Leerink Swann, LLC
Medical Marketing Studies U.S., Inc.
Newland Medical Associates, P.C.
Onyx Pharmaceuticals, Inc.
Pharmaceuticals, Inc.
Prime Oncology
Roche
sano-avents
Schering-Plough
StrataMed, LLC
Tennessee Oncology, PLLC
Walchi Tauber Group, Inc.
Wyeth
ZIOPHARM